Assessment of the proliferative and angiogenic effects of the synthetic cannabinoid (R)-5-fluoro ADB on human cerebral microvascular endothelial cells

Document Type : Original Article


1 Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan

2 Department of Anatomy, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia

3 Genomics and Personalized Medicine Unit, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia


Objective(s): The process of vascular formation, also known as angiogenesis, primarily relies on endothelial cell proliferation, migration, and invasion. In recent years, it has been discovered that synthetic cannabinoids (SCs) may potentially impact angiogenic processes within the body. We evaluated the impact of the synthetic cannabinoid (R)-5-Fluoro-ADB on the proliferation rate and angiogenesis in Human Cerebral Microvascular Endothelial Cells (hBMECs). 
Materials and Methods: hBMECs were treated with (R)-5-Fluoro-ADB and investigated for cell viability, migration rate, and tube-like structure formation. Furthermore, angiogenic-related proteins including Angopoitein-1 and -2, and Vascular Endothelial Growth Factors (VEGF) were examined on mRNA and protein levels.
Results: The results showed a notable rise in the rate of proliferation (P-value<0.0001) of HBMECs induced by (R)-5-Fluoro-ADB. The angiogenic capacity of HBMECs was also enhanced between 0.001 μM to 1 μM (R)-5-Fluoro-ADB. Moreover, an increase in the levels of ANG-1, ANG-2, and VEGF mRNA and protein, as well as elevated phosphorylation rate of GSK-3β, were observed across various concentrations of (R)-5-Fluoro-ADB.
Conclusion: Our results suggest an innovative approach in pharmacology for addressing a range of conditions linked to angiogenesis. This approach involves precise targeting of both cannabinoid receptors type-1 and -2. To achieve this, specific agonists or antagonists of these receptors could be employed based on the particular characteristics of the diseases in question.


Main Subjects

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
2. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O. Pericytes at the intersection between tissue regeneration and pathology. Clin Sci (Lond) 2015; 128:81-93.
3. Kerr AL, Steuer EL, Pochtarev V, Swain RA. Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition. Neuroscience 2010; 171:214-226.
4. Adair TH, Montani JP. Integrated systems physiology: From molecule to function to disease. Angiogenesis. San rafael (CA): Morgan & Claypool Life Sciences Copyright © 2010 by Morgan & Claypool Life Sciences.; 2010.
5. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999; 6:R217-R224.
6. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 2018; 59:455-467.
7. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006; 98:1014-1023.
8. Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 2019; 8:471-489.
9. Barr JL, Unterwald EM. Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs. Biochim Biophys Acta Mol Cell Res 2020; 1867:118746-118770.
10. Wadhwa P, Jain P, Jadhav HR. Glycogen synthase kinase 3 (GSK3): Its role and inhibitors. Curr Top Med Chem 2020; 20:1522-1534.
11. Leroy K, Brion JP. Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 1999; 16:279-293.
12. Kim HS, Skurk C, Thomas SR, Bialik A, Suhara T, Kureishi Y, et al. Regulation of angiogenesis by glycogen synthase kinase-3beta. J Biol Chem 2002; 277:41888-41896.
13.Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, et al. Glycogen synthase kinase-3: A new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101:2005-2014.
14. Corada M, Nyqvist D, Orsenigo F, Caprini A, Giampietro C, Taketo MM, et al. The wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell 2010; 18:938-949.
15.  Lutz B. Neurobiology of cannabinoid receptor signaling
dialogues. Clin Neurosci 2020; 22:207-222.
16. Alves VL, Gonçalves JL, Aguiar J, Teixeira HM, Câmara JS. The synthetic cannabinoids phenomenon: From structure to toxicological properties. A review. Crit Rev Toxicol 2020; 50:359-382.
17. Seither JZ, Reidy LJ, Boland DM. Identification and quantification of 5-fluoro ADB and the 5-fluoro ADB ester hydrolysis metabolite in postmortem blood samples by LC-MS/MS. J Anal Toxicol 2020; 44:133-139.
18. Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther 2017; 101:220-229.
19. McCain KR, Jones JO, Chilbert KT, Patton AL, James LP, Moran JH. Impaired driving associated with the synthetic cannabinoid 5f-Adb. J Forensic Sci Criminol 2018; 6:1-7.
20. Usui K, Fujita Y, Kamijo Y, Kokaji T, Funayama M. Identification of 5-fluoro ADB in human whole blood in four death cases. J Anal Toxicol 2018; 42:e21-e25.
21. Al-Eitan L, Alhusban A, Alahmad S. Effects of the synthetic cannabinoid XLR-11 on the viability and migration rates of human brain microvascular endothelial cells in a clinically-relevant model. Pharmacol Rep 2020; 72:1717-1724.
22. Rezabakhsh A, Nabat E, Yousefi M, Montazersaheb S, Cheraghi O, Mehdizadeh A, et al. Endothelial cells’ biophysical, biochemical, and chromosomal aberrancies in high-glucose condition within the diabetic range. Cell Biochem Funct 2017; 35:83-97.
23. Xiang Y, Yao X, Wang X, Zhao H, Zou H, Wang L, et al. Houshiheisan promotes angiogenesis via HIF-1α/VEGF and SDF-1/CXCR4 pathways: In vivo and in vitro. Biosci Rep 2019; 39:1-12.
24. Al-Eitan L, Alahmad S. The expression analyses of GSK3B, VEGF, ANG1, and ANG2 in human brain microvascular endothelial cells treated with the synthetic cannabinoid XLR-11. Gene 2023; 878:147585.
25. Busquets-Garcia A, Bains J, Marsicano G. CB(1) receptor signaling in the brain: extracting specificity from ubiquity. Neuropsychopharmacology 2018; 43:4-20.
26. Sezer Y, Jannuzzi AT, Huestis MA, Alpertunga B. In vitro assessment of the cytotoxic, genotoxic and oxidative stress effects of the synthetic cannabinoid JWH-018 in human SH-SY5Y neuronal cells. Toxicol Res (Camb) 2020; 9:734-740.
27. Cerretani D, Collodel G, Brizzi A, Fiaschi AI, Menchiari A, Moretti E, et al. Cytotoxic effects of cannabinoids on human HT-29 colorectal adenocarcinoma cells: Different mechanisms of THC, CBD, and CB83. Int J Mol Sci 2020; 21: 5533-5547.
28. Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. In vitro cell migration and invasion assays. J Vis Exp 2014; 88: 51046-51053.
29. Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 2011; 117:5541-5550.
30. Lingegowda H, Miller JE, Marks RM, Symons LK, Alward T, Lomax AE, et al. Synthetic cannabinoid agonist WIN 55212-2 targets proliferation, angiogenesis, and apoptosis via MAPK/AKT signaling in human endometriotic cell lines and a murine model of endometriosis. Front Reprod Health 2021; 3:726936-726949.
31. Benedicto A, Arteta B, Duranti A, Alonso-Alconada D. The synthetic cannabinoid URB447 Exerts antitumor and antimetastatic effect in melanoma and colon cancer. Pharmaceuticals (Basel) 2022; 15:1166-1176.
32. Moritz F, Schniering J, Distler JHW, Gay RE, Gay S, Distler O, et al. Tie2 as a novel key factor of microangiopathy in systemic sclerosis. Arthritis Res Ther 2017; 19:105-115.
33. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34:1785-1788.
34. Blázquez C, Casanova ML, Planas A, Gómez Del Pulgar T, Villanueva C, Fernández-Aceñero MJ, et al. Inhibition of tumor angiogenesis by cannabinoids. Faseb j 2003; 17:529-531.
35. Hartigan JA, Johnson GV. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem 1999; 274:21395-21401.
36. Luo J. The role of GSK3beta in the development of the central nervous system. Front Biol (Beijing) 2012; 7:212-220.
37. Krishnankutty A, Kimura T, Saito T, Aoyagi K, Asada A, Takahashi SI, et al. In vivo regulation of glycogen synthase kinase 3β activity in neurons and brains. Sci Rep 2017; 7:8602-8616.
38.Zhao P, Li Q, Shi Z, Li C, Wang L, Liu X, et al. GSK-3β regulates tumor growth and angiogenesis in human glioma cells. Oncotarget 2015; 6:31901-31915.
39. Holmes T, O’Brien TA, Knight R, Lindeman R, Symonds G, Dolnikov A. The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis and leukaemia. Curr Med Chem 2008; 15:1493-1499.
40. Trazzi S, Steger M, Mitrugno VM, Bartesaghi R, Ciani E. CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/glycogen synthase kinase-3beta/beta-catenin signaling. J Biol Chem 2010; 285:10098-10109.